Background In the 5 years that have passed since the publication of the 2018 International
Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis …

Chronic cough is globally prevalent across all age groups. This disorder is challenging to
treat because many pulmonary and extrapulmonary conditions can present with chronic …

Background Gefapixant is an oral P2X 3 receptor antagonist that has previously shown
efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore …

Background The inability to test at scale has become humanity's Achille's heel in the
ongoing war against the COVID-19 pandemic. A scalable screening tool would be a game …

These guidelines incorporate the recent advances in chronic cough pathophysiology,
diagnosis and treatment. The concept of cough hypersensitivity has allowed an umbrella …

Background Critical examination of the quality and validity of available allergic rhinitis (AR)
literature is necessary to improve understanding and to appropriately translate this …

Importance The National Action Plan for Combating Antibiotic-Resistant Bacteria set a goal
of reducing inappropriate outpatient antibiotic use by 50% by 2020, but the extent of …

Background We performed systematic reviews using the population, intervention,
comparison, outcome (PICO) format to answer the following key clinical question: Are the …

Background Gefapixant is a P2X3 receptor antagonist that has shown promise for the
treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate …

Cough is an essential defence mechanism [1]. However, chronic cough is a significant
cause of morbidity, seriously impairing quality of life [2]. Previously, chronic cough was …